Indolent B-cell Non-hodgkin Lymphoma

• CLINICAL_TRIALS trial_result · 2026-03-20
  Clinical Trial Update: ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  A Phase 1/2 study evaluating ALX148 in combination with Rituximab and Lenalidomide for various B-cell non-Hodgkin lymphomas, with the trial …

• CLINICAL_TRIALS trial_result · 2025-11-05
  Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) [Phase 2]

  This is a Phase 2 clinical trial evaluating JCAR017 (lisocabtagene maraleucel) in adults with relapsed or refractory indolent B-cell non-Hod…

• CLINICAL_TRIALS trial_result · 2025-04-24
  Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]

  Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory …

• CLINICAL_TRIALS trial_result · 2025-04-11
  Clinical Trial Update: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma [Phase 2]

  A Phase 2 clinical trial evaluating mosunetuzumab with or without polatuzumab vedotin and obinutuzumab for untreated indolent B-cell non-Hod…

• CLINICAL_TRIALS trial_result · 2024-07-03
  Clinical Trial Update: QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab [Phase 1, Phase 2]

  The QUILT-3.002 trial evaluating N-803 in combination with Rituximab for relapsed/refractory indolent B-cell non-Hodgkin lymphoma has been t…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2022-12-30
  Clinical Trial Update: Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases [Phase 2]

  A Phase 2 pembrolizumab trial in untreated B-cell non-Hodgkin lymphoproliferative diseases has been terminated; results have been posted.

• CLINICAL_TRIALS trial_result · 2021-01-07
  Clinical Trial Update: A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma [Phase 2]

  Phase 2 trial evaluating Rituxan (rituximab) with beta-glucan PGG in relapsed indolent B-cell non-Hodgkin lymphoma has completed, with resul…

• CLINICAL_TRIALS trial_result · 2020-09-30
  Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection [Phase 2]

  Phase 2 trial evaluating bendamustine hydrochloride injection for indolent B-cell non-Hodgkin's lymphomas has completed.

• CLINICAL_TRIALS trial_result · 2018-08-09
  Clinical Trial Update: Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) [Phase 2]

  Phase 2 trial assessing ofatumumab and bendamustine followed by maintenance ofatumumab for rituximab-relapsed indolent B-cell non-Hodgkin's …

• CLINICAL_TRIALS trial_result · 2018-07-26
  Clinical Trial Update: GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma [Phase 1]

  Phase 1 study evaluating GP2013, a rituximab biosimilar, in Japanese patients with CD20-positive low-tumor-burden indolent B-cell non-Hodgki…

• CLINICAL_TRIALS trial_result · 2018-02-28
  Clinical Trial Update: Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma [Phase 1]

  This document notes the completion of a Phase 1 drug-drug interaction study of Ofatumumab with Bendamustine in indolent B-cell non-Hodgkin l…

• CLINICAL_TRIALS trial_result · 2014-08-21
  Clinical Trial Update: A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas [Phase 2]

  Phase 2 study evaluating induction and maintenance Rituximab (MabThera) in patients with indolent B-cell non-Hodgkin lymphoma; trial complet…

• CLINICAL_TRIALS trial_result · 2014-08-06
  Clinical Trial Update: Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma [Phase 1]

  Phase 1 trial update describing treatment with genetically engineered lymphocytes, cyclophosphamide, and aldesleukin in relapsed or refracto…

• CLINICAL_TRIALS trial_result · 2012-08-28
  Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL) [Phase 2]

  Phase 2 study evaluating the efficacy and safety of combining bendamustine with ofatumumab as first-line therapy for indolent B-cell non-Hod…